Will Resmetirom Prove to be a Gamechanger in NASH?
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company, is developing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, an approach that has the potential to address the unmet needs in cardiovascular, metabolic and fatty liver diseases. The Company’s research is...
